These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 27138571)

  • 41. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
    Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
    Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.
    Riff BP; Yang YX; Soulen MC; Pryma DA; Bennett B; Wild D; Nicolas G; Teitelbaum UR; Metz DC
    Clin Nucl Med; 2015 Nov; 40(11):845-50. PubMed ID: 26284763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK; Khan MS; Toumpanakis C; Caplin ME
    Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
    Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
    Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
    [No Abstract]   [Full Text] [Related]  

  • 48. Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context.
    Wagner M; Samaha D; Cuervo J; Patel H; Martinez M; O'Neil WM; Jimenez-Fonseca P
    Adv Ther; 2018 Aug; 35(8):1215-1231. PubMed ID: 29987525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
    Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
    Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pancreatic neuroendocrine tumors: a review.
    Young K; Iyer R; Morganstein D; Chau I; Cunningham D; Starling N
    Future Oncol; 2015; 11(5):853-64. PubMed ID: 25757686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment with
    Estorch M
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748
    [No Abstract]   [Full Text] [Related]  

  • 52. NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):8-9. PubMed ID: 27168104
    [No Abstract]   [Full Text] [Related]  

  • 53. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
    Kesavan M; Claringbold PG; Turner JH
    Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
    J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
    Garcia-Carbonero R; Garcia-Figueiras R; Carmona-Bayonas A; Sevilla I; Teule A; Quindos M; Grande E; Capdevila J; Aller J; Arbizu J; Jimenez-Fonseca P;
    Cancer Metastasis Rev; 2015 Dec; 34(4):823-42. PubMed ID: 26433592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endoscopic imaging in the management of gastroenteropancreatic neuroendocrine tumors.
    Pellicano R; Fagoonee S; Altruda F; Bruno M; Saracco GM; De Angelis C
    Minerva Endocrinol; 2016 Dec; 41(4):490-8. PubMed ID: 27600643
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
    Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
    J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of Diarrhea in Patients With Carcinoid Syndrome.
    Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
    Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.